RU2017117253A - Наргенициновые соединения и их применение в качестве антибактериальных средств - Google Patents

Наргенициновые соединения и их применение в качестве антибактериальных средств Download PDF

Info

Publication number
RU2017117253A
RU2017117253A RU2017117253A RU2017117253A RU2017117253A RU 2017117253 A RU2017117253 A RU 2017117253A RU 2017117253 A RU2017117253 A RU 2017117253A RU 2017117253 A RU2017117253 A RU 2017117253A RU 2017117253 A RU2017117253 A RU 2017117253A
Authority
RU
Russia
Prior art keywords
alkyl
ring
arya
optionally substituted
independently selected
Prior art date
Application number
RU2017117253A
Other languages
English (en)
Russian (ru)
Other versions
RU2017117253A3 (enExample
Inventor
Кэтрин ЯНГ
Дэвид Б. Олсен
Шео Б. СИНГХ
Цзин СУ
Роберт Р. Вилкенинг
Джеймс М. Эпгар
Дунфан МЭН
Данн ПАРКЕР
Михир МЭНДАЛ
Лиху Ян
Роланд Е. ПЕЙНТЕР
Цюнь Дан
Такао СУДЗУКИ
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of RU2017117253A publication Critical patent/RU2017117253A/ru
Publication of RU2017117253A3 publication Critical patent/RU2017117253A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
RU2017117253A 2014-10-22 2015-10-21 Наргенициновые соединения и их применение в качестве антибактериальных средств RU2017117253A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2014/089204 WO2016061772A1 (en) 2014-10-22 2014-10-22 Nargenicin compounds and uses thereof as antibacterial agents
CNPCT/CN2014/089204 2014-10-22
PCT/US2015/056627 WO2016064982A1 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents

Publications (2)

Publication Number Publication Date
RU2017117253A true RU2017117253A (ru) 2018-11-23
RU2017117253A3 RU2017117253A3 (enExample) 2019-04-16

Family

ID=55760063

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017117253A RU2017117253A (ru) 2014-10-22 2015-10-21 Наргенициновые соединения и их применение в качестве антибактериальных средств

Country Status (11)

Country Link
US (2) US9944654B2 (enExample)
EP (1) EP3209667B1 (enExample)
JP (1) JP2017533200A (enExample)
KR (1) KR20170070197A (enExample)
CN (1) CN107108646A (enExample)
AU (1) AU2015335992A1 (enExample)
BR (1) BR112017008101A2 (enExample)
CA (1) CA2964377A1 (enExample)
MX (1) MX2017005271A (enExample)
RU (1) RU2017117253A (enExample)
WO (2) WO2016061772A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
KR102440647B1 (ko) 2020-07-28 2022-09-06 선문대학교 산학협력단 나르제니신 a1 유도체를 포함하는 항혈관신생용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148883A (en) 1977-08-18 1979-04-10 Pfizer Inc. Antibiotics produced by new species of nocardia
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4351769A (en) * 1980-08-25 1982-09-28 The Upjohn Company Antibiotic composition of matter
US4448970A (en) * 1981-02-19 1984-05-15 The Upjohn Company Nargenicin derivatives
US4605624A (en) * 1982-10-21 1986-08-12 Pfizer Inc. Nocardia species capable of producing nargenicin C1
US4436747A (en) 1982-10-21 1984-03-13 Pfizer Inc. Nargenicin C1
MXPA05001558A (es) 2002-08-12 2005-09-08 Pharmacia & Upjohn Co Llc N-aril-2-oxazolidinonas y sus derivados.
CA2507628A1 (en) 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
GB0227701D0 (en) 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
US20070197541A1 (en) 2003-07-29 2007-08-23 Oyelere Adegboyega K Biaryl heterocyclic amines,amides, and sulfur-containing compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
JP2008500318A (ja) 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての3−{4−(ピリジン−3−イル)フェニル}−5−(1h−1,2,3−トリアゾール−1−イルメチル)−1,3−オキサゾリジン−2−オン
WO2007133803A2 (en) 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008069619A1 (en) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
KR101040468B1 (ko) 2008-02-29 2011-06-09 조선대학교산학협력단 새로운 노카르디아 속 균주 및 그의 발효 배양물의 용도
KR101022564B1 (ko) 2008-12-19 2011-03-16 조선대학교산학협력단 나르제니신을 포함하는 염증성 신경퇴행성 질환의 치료용 제약 조성물
WO2011139832A2 (en) 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Also Published As

Publication number Publication date
KR20170070197A (ko) 2017-06-21
MX2017005271A (es) 2017-08-15
CA2964377A1 (en) 2016-04-28
JP2017533200A (ja) 2017-11-09
EP3209667B1 (en) 2025-03-19
WO2016064982A1 (en) 2016-04-28
BR112017008101A2 (pt) 2018-02-20
US10144741B2 (en) 2018-12-04
US20170305924A1 (en) 2017-10-26
EP3209667A4 (en) 2018-06-06
EP3209667A1 (en) 2017-08-30
US20180186808A1 (en) 2018-07-05
US9944654B2 (en) 2018-04-17
RU2017117253A3 (enExample) 2019-04-16
AU2015335992A1 (en) 2017-04-20
CN107108646A (zh) 2017-08-29
WO2016061772A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
MY202837A (en) Lipids for lipid nanoparticle delivery of active agents
RU2018134948A (ru) Бициклические арильные монобактамовые соединения и способы их применения для лечения бактериальных инфекций
JP2019500387A5 (enExample)
JP2019507768A5 (enExample)
JP2019537570A5 (enExample)
JP2015514808A5 (enExample)
RU2016134751A (ru) Соединения
JP2014500295A5 (enExample)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2017523169A5 (enExample)
JP2013529196A5 (enExample)
JP2016506369A5 (enExample)
RU2013149174A (ru) Новое имидазооксазиновое соединение или его соль
JP2013502431A5 (enExample)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2016516043A5 (enExample)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2013523614A5 (enExample)
JP2013512903A5 (enExample)
JP2013526559A5 (enExample)
JP2016527217A5 (enExample)
JP2021534095A5 (enExample)
JP2017519754A5 (enExample)
RU2014107484A (ru) ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2
JP2015536947A5 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191217

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20191217